NPS Pharmaceuticals
NPS Pharmaceuticals is a former U.S. rare-disease biopharmaceutical company, founded in 1986 and acquired by Takeda in 2015 for ~$5.2 billion, whose Gattex/Revestive and Natpara products for short bowel syndrome and hypoparathyroidism now operate within Takeda's global rare disease franchise.
- Company typePublic
- Founded1986
- HeadquartersBedminster, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What NPS Pharmaceuticals does
NPS Pharmaceuticals was a U.S.-based, rare-disease-focused biopharmaceutical company founded in 1986 and headquartered in Bedminster, New Jersey. The company developed and commercialized specialty therapeutics for ultra-rare conditions, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. Its commercial model centered on selling high-priced orphan drugs to a small but clinically dependent patient population through specialty pharmacy and physician channels, generating revenue via direct prescription sales. NPS was acquired by Takeda Pharmaceutical Company Limited in 2015 for approximately $5.2 billion and was subsequently delisted from NASDAQ; its products and capabilities were integrated into Takeda's rare disease franchise. Following the acquisition, NPS ceased to operate as an independent reporting entity, and the data now attributed to the NPS profile largely reflects its parent Takeda's global pharmaceutical operations across 70+ countries, including a robust pipeline in neuroscience, immunology, oncology, and rare diseases. As of mid-2026, the inherited NPS capabilities continue to be exercised through Takeda's enterprise field sales organization, global manufacturing infrastructure (including facilities referenced in legacy NPS production), and Phase 3 pipeline assets such as oveporexton for narcolepsy Type 1 and zasocitinib for psoriasis.
NPS Pharmaceuticals firmographics
Firmographics- Name
- NPS Pharmaceuticals
- Legal name
- Takeda Pharmaceutical Company Limited
- Website
- https://npsp.com
- Company type
- Public
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- NPS Pharmaceuticals is a former U.S. rare-disease biopharmaceutical company, founded in 1986 and acquired by Takeda in 2015 for ~$5.2 billion, whose Gattex/Revestive and Natpara products for short bowel syndrome and hypoparathyroidism now operate within Takeda's global rare disease franchise.
- Ownership category
- akta.pro rank
NPS Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals (Rare Disease Therapeutics)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)
- akta.pro secondary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where NPS Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Bedminster
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
NPS Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Revenue model
- Prescription Pharmaceuticals: Takeda generates revenue through the development, manufacture, and sale of prescription pharmaceutical products globally. Revenue comes from both proprietary in-house developed drugs and acquired product lines including former NPS Pharmaceuticals products like Gattex/Revestive and Natpara.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
NPS Pharmaceuticals product offering
Product offeringCore offering
NPS Pharmaceuticals developed and commercialized prescription therapeutics for rare diseases, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. The company operated an internal R&D pipeline targeting rare and specialty disease indications and relied on proprietary drug development and advanced manufacturing processes. Following its 2015 acquisition by Takeda, these products are sold through Takeda's global pharmaceutical commercial organization.
Product overview
No product information for NPS Pharmaceuticals found in the source data. The source data is from Takeda Pharmaceuticals website and does not contain information about NPS Pharmaceuticals products or services.
Differentiator
Problem solved
Functional benefit
Brands
- TakedaEdge: A generational promise initiative where Takeda leads with bold reinvention for a healthier world, embracing cutting-edge science, technology and partnerships to create new standards of care.
Products and services
- Gattex/Revestive (teduglutide) A proprietary GLP-2 analog indicated for the treatment of short bowel syndrome (SBS) in adult and pediatric patients who are dependent on parenteral support. It is prescribed by specialists (e.g., gastroenterologists) for patients with rare gastrointestinal conditions.
- Natpara (parathyroid hormone) A recombinant parathyroid hormone product indicated as an adjunct to calcium and vitamin D for the treatment of hypoparathyroidism in adult patients who cannot be adequately controlled on calcium and vitamin D alone. Used by endocrinologists managing patients with this rare endocrine disorder.
Quantifiable outcome
- Oveporexton showed improved daily function, cognition, and nighttime sleep for people with narcolepsy Type 1 in pivotal studies
- +1 more outcomes
Companies that use NPS Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
NPS Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
NPS Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NPS PharmaceuticalscoreTakeda acquired NPS Pharmaceuticals in 2015 for approximately $5.2 billion, gaining control of NPS's rare disease portfolio including Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. This acquisition strengthened Takeda's rare disease franchise and expanded its specialty pharma capabilities.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
NPS Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Shire (now part of Takeda): Pre-acquisition rare-disease leader acquired by Takeda in 2019. Operates within the same Takeda parent as NPS and represents the larger rare-disease incumbent under the same corporate umbrella.
- Genzyme (Sanofi Rare Disease): Pioneering rare-disease franchise within Sanofi, with a broad orphan-drug portfolio across lysosomal storage, oncology, and immunology. Larger incumbent operating in adjacent rare-disease categories.
Direct peers
- BioMarin Pharmaceutical: Specialty biopharmaceutical company focused exclusively on rare diseases, with a portfolio of enzyme replacement and gene therapies addressing small patient populations — directly comparable business model and orphan-drug strategy to NPS.
- Vertex Pharmaceuticals: Specialty pharma focused on serious diseases with high unmet need (cystic fibrosis, sickle cell, pain). Comparable as a rare/specialty-disease-focused innovator with concentrated product franchises.
- Alexion Pharmaceuticals (AstraZeneca Rare Disease): Rare-disease specialist built around high-priced biologics for ultra-rare conditions, later acquired by AstraZeneca. Closely mirrors NPS's rare-disease, high-price-per-patient, biologic-led model.
- Swedish Orphan Biovitrum (Sobi): European specialty biopharma focused on rare diseases, particularly in immunology, hematology, and endocrinology. Closely aligned with NPS's rare-endocrine and orphan-biologic positioning.
- Ultragenyx Pharmaceutical: Pure-play rare-disease biotech developing and commercializing therapies for rare and ultra-rare genetic conditions. Directly comparable orphan-drug commercial and development model.
- Recordati Rare Diseases: Specialty pharma division focused exclusively on rare diseases, including endocrine and metabolic disorders. Directly comparable orphan-disease commercial strategy and patient-by-patient distribution model.
Emerging players
- Amicus Therapeutics: Clinical-stage and commercial rare-disease biotech with a focus on lysosomal storage disorders and rare-chemistry therapies. Comparable as a smaller, emerging rare-disease specialist building an orphan franchise.
- Reata Pharmaceuticals (now Biogen): Rare-disease biotech with FDA-approved therapies for ultra-rare conditions, acquired by Biogen in 2023. Comparable exit trajectory and rare-disease commercialization model to NPS.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
NPS Pharmaceuticals social profiles
Digital presenceNPS Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
NPS Pharmaceuticals leadership team
Management profileNumber of profiles
NPS Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NPS Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NPS Pharmaceuticals
What does NPS Pharmaceuticals do?
NPS Pharmaceuticals developed and commercialized prescription therapeutics for rare diseases, most notably Gattex/Revestive (teduglutide) for short bowel syndrome and Natpara (parathyroid hormone) for hypoparathyroidism. The company operated an internal R&D pipeline targeting rare and specialty disease indications and relied on proprietary drug development and advanced manufacturing processes. Following its 2015 acquisition by Takeda, these products are sold through Takeda's global pharmaceutical commercial organization.
Is NPS Pharmaceuticals a public or private company?
NPS Pharmaceuticals is a public company. It is classified as corporate owned and is currently operating.
When was NPS Pharmaceuticals founded?
NPS Pharmaceuticals was founded in 1986. It employs 5,001 to 10,000 people.
Where is NPS Pharmaceuticals based?
NPS Pharmaceuticals is headquartered in Bedminster, United States, in the North America region.
How does NPS Pharmaceuticals make money?
One revenue line is on record: prescription Pharmaceuticals.
Who are NPS Pharmaceuticals's main competitors?
Broad incumbents on record are Shire (now part of Takeda) and Genzyme (Sanofi Rare Disease). Direct peers are BioMarin Pharmaceutical, Vertex Pharmaceuticals, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Swedish Orphan Biovitrum (Sobi), Ultragenyx Pharmaceutical and Recordati Rare Diseases. Emerging players are Amicus Therapeutics and Reata Pharmaceuticals (now Biogen).
Does NPS Pharmaceuticals have an API?
No public API is recorded for NPS Pharmaceuticals.
What industry is NPS Pharmaceuticals in?
NPS Pharmaceuticals's product category is Specialty Pharmaceuticals (Rare Disease Therapeutics). Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.